preheader BJH 1

header website

Highlights Newsletter 1

This newsletter presents you the following key sessions:

1. Video-interview with Professor Meletios Dimopoulos, MD, National and Kapodistrian University of Athens School
    of Medicine, Athens, Greece

2. Classic Hodgkin lymphoma (cHL) patients with high-risk features have greater benefit from brentuximab vedotin
    + AVD versus ABVD compared with the overall study population

3. Anti-tumor activity of compound CAR T cells targeting both CLL1 and CD33 in a variety of CLL1+ and CD33+
    leukemia cells in vitro and in vivo

4. Better response rates and increased MRD negativity with KRd compared to KCd in newly diagnosed multiple
    myeloma patients, including high-risk patients

5. The combination of ruxolitinib and azacitidine is well tolerated with good responses in patients with myelofibrosis



Tom Feys, MSc


Medical writer

Back to Top